ZAVESKY, Ludek, Eva JANDÁKOVÁ, Vít WEINBERGER, Luboš MINÁŘ, Milada KOHOUTOVA and Ondrej SLANAR. Human Endogenous Retroviruses in Breast Cancer: Altered Expression Pattern Implicates Divergent Roles in Carcinogenesis. Oncology. Basel: Karger, 2024, 10 pp. ISSN 0030-2414. Available from: https://dx.doi.org/10.1159/000538021.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Human Endogenous Retroviruses in Breast Cancer: Altered Expression Pattern Implicates Divergent Roles in Carcinogenesis
Authors ZAVESKY, Ludek, Eva JANDÁKOVÁ, Vít WEINBERGER, Luboš MINÁŘ, Milada KOHOUTOVA and Ondrej SLANAR.
Edition Oncology, Basel, Karger, 2024, 0030-2414.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.500 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1159/000538021
UT WoS 001243070800001
Keywords in English Breast cancer; Human endogenous retroviruses; ERVW-1; ERVFRD-1; ERVV-1; ERV3-1; ERVH48-1; ERVMER34-1; ERVK13-1; ERVK3-1; HCP5
Tags 14110230, 14110240
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 2/7/2024 09:53.
Abstract
Introduction: Breast cancer is the most common cancer and the leading cause of cancer death in women. Recent research indicates that human endogenous retroviruses (HERVs) may be linked to carcinogenesis, but the data remain controversial. Methods: HERVs' expression was evaluated to show the differences between breast cancer and control samples, and their associations with clinicopathological parameters. Gene expression of 12 HERVs, i.e., ERVE-4, ERVW-1, ERVFRD-1, ERVV-1, ERV3-1, ERVH48-1, ERVMER34-1, ERVK-7, ERVK13-1, ERVK11-1, ERVK3-1, and HCP5, was analyzed by qPCR and/or TCGA datasets for breast cancer. Results: ERV3-1, ERVFRD-1, ERVH48-1, and ERVW-1 provided data to support their tumor suppressor roles in breast cancer. ERV3-1 evinced the best performing diagnostic data based on qPCR, i.e., AUC: 0.819 (p < 0.0001), sensitivity of 72.41%, and specificity of 89.66%. Lower levels of ERV3-1 were noted in advanced stage and higher grades, and significant negative association was found in relation to Ki-67 levels. Oncogenic roles may be inferred for ERVK13-1, ERVV-1, and ERVMER34-1. Data for ERVK-7, ERVE-4, ERVK11-1, and HCP5 remain inconclusive. Conclusion: Differential HERV expression may be applicable to evaluate novel biomarkers for breast cancer. However, more research is needed to reveal their real clinical impact, the biological roles, and regulatory mechanisms in breast carcinogenesis. (c) 2024 The Author(s).Published by S. Karger AG, Basel
PrintDisplayed: 24/7/2024 16:31